The UK and US have reached a key bilateral deal that will keep no tariffs on British drug shipments going into the American market.
Key Provisions of the Pact
In exchange for the tariff guarantee, the UK has agreed to increase funding on drugs through the National Health Service (NHS). This commitment guarantees that duties on these vital exports will stay at nothing for a timeframe of three years.
This agreement is in response to recent statements to significantly raise tariffs on patented drug imports, with figures mentioned reaching double the cost.
"This agreement between the UK strengthens the global environment for innovative medicines and introduces long-overdue equity to transatlantic medicine commerce," a release said.
Trade Impact
Drugs represent one of the UK's most significant export categories to the America, which is by far the biggest market for large UK drugmakers.
Statistics indicate that in the one-year period to the end of the third quarter, the UK shipped drugs valued at over eleven billion pounds to the US. This amount made up 17.4% of all goods exports in that span.
"This deal secures employment, stimulates funding and sets the stage for the UK to become a international leader for biotech and pharma," a minister commented.
Detailed UK Commitments
The pact involves several key changes from the British government:
- Price Threshold Increase: The UK will raise the price threshold at which it considers new therapies to be too expensive by a quarter.
- Higher Drug Budget: There is a aim to double total NHS spending on drugs from 0.3% of the national economy to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to stay within budget will be restricted at 15%. In the past, refunds topped twenty percent.
Industry Background
This agreement takes place against a protracted dispute between the sector and the British authorities over drug pricing and regulatory access.
The disagreement were heightened by claims that American patients were paying a premium for the same drugs than consumers in the Britain and the EU.
Over the last 18 months, several significant drug company projects in the UK have been halted or abandoned, while substantial funding commitments have been directed toward projects in the United States.
A senior figure acknowledged that the NHS must invest a greater share on medicines, noting that its spending on drugs had shrunk as a percentage of its resources over the last ten years.
